DEA Revokes Beverly Hills Doc's License Over Safety Risks
Published Date: 2/10/2025
Notice
Summary
Dr. David Bockoff from Beverly Hills had his DEA registration suspended and is now losing it because he was found to be a danger to public health and safety. After a fair hearing, the decision to revoke his registration was confirmed, meaning he can no longer legally handle controlled substances. This affects Dr. Bockoff directly and signals a serious step to protect the public, with no money penalties mentioned but a clear end to his DEA privileges.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Bockoff
Dr. David Bockoff (DEA registration No. BB4591839) had his DEA registration immediately suspended on October 25, 2022 and, after a hearing held January 19–24, 2023 and an ALJ recommendation on May 2, 2023, the Agency confirmed revocation in a Decision and Order published February 10, 2025. As a result, Dr. Bockoff can no longer legally handle or prescribe controlled substances; the notice does not mention any monetary penalties.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
Previous / Next Documents
Previous: 2025-02420 — Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Some companies want to become or grow as bank holding companies by merging with or buying banks. If you’re involved in banking or interested, you can share your thoughts by March 12, 2025. These moves could change who controls certain banks and might affect local banking options and money flow.
Next: 2025-02422 — Potassium Chloride (KCl); Receipt of Application for Emergency Exemption
The Idaho State Department of Agriculture wants to use potassium chloride to fight Quagga mussels on 1.26 acres. Since this chemical isn’t EPA-approved yet, they asked for a quick emergency OK. Because it’s urgent and limited, EPA skipped the usual public comment but still welcomes info from anyone interested.